Does nesiritide reduce death and rehospitalization in patients with acute decompensated heart failure?
Nesiritide does not improve death, rehospitalization, or dyspnea in acute heart failure and increases hypotension, and thus cannot be recommended for routine use.
Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.).
O’Connor et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: